NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

HPRA listed by US Food and Drug Administration as part of agreement between EU and US

By Mindo - 07th Jun 2018

This follows the EU and US authorities signing a mutual recognition agreement (MRA) that entered into force on 1 November 2017 with a transition phase for recognition of EU Member States until July 2019. The MRA contains a sectoral annex on the mutual recognition of pharmaceutical good manufacturing practice (GMP). 

The MRA comes as a result of assessments of both the EU national competent authorities’ (NCAs) and FDA’s inspection systems. In June 2017, the European Commission confirmed that the FDA has the capability, capacity and procedures in place to carry out GMP inspections at a level equivalent to the EU. An audit of the HPRA’s GMP inspection system, under the joint audit programme (JAP), took place from 15 to 19 May 2017 and was observed by FDA investigators.

 <br />The initial scope of the MRA includes human medicines and biological medicines.Veterinary medicines are excluded at this time but a decision on their inclusion will be made no later than July 2019. Full details on the scope of products included in the EU-US mutual recognition agreement can be found here:    

Moreover, a direct result of Ireland being included on the list, the FDA can now rely on HPRA inspections to replace their own inspections. 

<br />This should result in reduced number of FDA inspections of manufacturers located in Ireland and reduced number of HPRA inspections of US manufacturers. There would also be improved efficiency of assessments involving contract manufacturing sites based in the US and increased inspection resources available to inspect in other parts of the world where active pharmaceutical ingredients and medicines for the EU or US markets are manufactured.

<br />Although the intent of the MRA is to rely on the factual findings in official GMP documents shared between inspectorates, the MRA does permit circumstances whereby EU national competent authorities or FDA will conduct their own inspections in each other’s territory.

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read